Statute Details
- Title: Health Products (Clinical Trials) Regulations 2016
- Act Code: HPA2007-S331-2016
- Type: Subsidiary legislation (SL)
- Enacting Act: Health Products Act (Cap. 122D), made under section 72
- Regulator: Health Sciences Authority (HSA), with approval of the Minister for Health
- Commencement: 1 November 2016
- Status: Current version as at 27 March 2026
- Parts: Part 1 (General); Part 2 (Clinical trials of therapeutic products or applicable CTGT products); Part 3 (Miscellaneous); Part 4 (Offences); Part 5 (Application to pending clinical trials)
- Key definitions (examples): “adverse event”, “adverse drug reaction”, “CTGT product”, “applicable CTGT product”, “clinical trial in an emergency situation”, “investigational product”, “auxiliary product”, “sponsor”, “principal investigator”
- Key provisions (high level): Scope (reg. 3); authorisation/notification (regs. 7–12); good clinical practice and conduct (regs. 13–15); consent and information (regs. 16–20); safety measures and trial suspension/termination (regs. 21–22); records and traceability (regs. 23–23A); vigilance reporting (regs. 24–25); labelling (reg. 26); confidentiality and publication (regs. 27–28); offences (reg. 29); pending trials (reg. 30)
- Schedules: First Schedule (Principles of good clinical practice); Second Schedule (Labelling requirements)
What Is This Legislation About?
The Health Products (Clinical Trials) Regulations 2016 (“CT Regulations”) set out the regulatory framework for conducting clinical trials in Singapore involving regulated health products—principally therapeutic products and certain cell, tissue and gene therapy products (“CTGT products”). In plain terms, the Regulations require sponsors and investigators to obtain the right permissions (or make the right notifications), follow good clinical practice, protect research subjects, and report safety information to the Health Sciences Authority (HSA).
The Regulations are designed to ensure that clinical trials are conducted ethically and safely, with appropriate oversight of trial design, subject consent, investigational product handling, and ongoing vigilance. They also create enforceable duties—backed by offences—so that non-compliance can trigger regulatory consequences.
Importantly, the scope is not limited to “therapeutic products” alone. The Regulations also cover “applicable CTGT products” (a category linked to the CTGT product classification framework under the Health Products (Cell, Tissue and Gene Therapy Products) Regulations 2021). This means that trials involving certain advanced therapies are brought within a structured compliance regime, including traceability and labelling requirements.
What Are the Key Provisions?
1. Scope and applicability (reg. 3)
The Regulations apply to “all clinical trials” of specified product categories that are not observational. This is a critical threshold: if a study is observational rather than interventional, the CT Regulations may not apply in the same way. For practitioners, the classification of the study design (interventional vs observational) and the product category (therapeutic vs CTGT, and whether it is an “applicable CTGT product”) will determine the compliance pathway.
2. Sponsor and investigator responsibilities (regs. 4–6)
The Regulations allocate roles and responsibilities. A sponsor is the party that initiates, manages, and finances (or arranges financing for) the trial. The principal investigator (and related investigator roles) is responsible for the conduct of the trial at the site level. The Regulations also require an investigator’s brochure, which is a structured compilation of clinical and non-clinical data relevant to the investigational product. This supports informed decision-making by investigators and helps ensure that trial conduct is grounded in available evidence.
3. Authorisation or notification: the regulatory gatekeeping (regs. 7–12)
A central feature is the requirement for either authorisation or notification for clinical trials, depending on the regulatory classification and circumstances. The Regulations distinguish between:
- Authorisation pathway (including an application process): the sponsor must obtain HSA authorisation before conducting the trial in specified cases.
- Notification pathway: in other cases, the sponsor may be required to notify HSA rather than obtain prior authorisation.
The Regulations also address practical compliance issues: how to apply (reg. 8), how to notify (reg. 9), and how to manage amendments and substantial amendments (reg. 10). Substantial amendments typically require heightened scrutiny because they may materially affect subject safety, trial conduct, or scientific validity.
4. Safety communications and trial status (regs. 11–12)
The Regulations impose vigilance-style reporting obligations even during the trial. Sponsors must notify HSA of serious breaches and urgent safety measures (reg. 11). They must also notify the status of the clinical trial (reg. 12), which supports regulatory visibility over trial progress, completion, or discontinuation.
5. Good clinical practice and compliance with permissions (regs. 13–15)
The Regulations require that clinical trials be conducted in accordance with good clinical practice (reg. 13), and specifically in accordance with the authorisations and notifications granted/accepted by HSA (reg. 14). This means that trial teams cannot treat HSA submissions as mere administrative steps; the approved protocol and conditions become binding operational constraints.
Regulation 15 addresses the place of clinical trial, ensuring that trials occur in appropriate settings and under appropriate governance. For legal practitioners, this is often relevant where multi-site trials are conducted or where trial activities are delegated to different facilities.
6. Consent, information duties, and emergency exceptions (regs. 16–20)
The Regulations contain a detailed consent framework. In general, subjects must provide consent in accordance with the Regulations (reg. 16), and there are special rules for emergency situations (reg. 17) where consent cannot be obtained in the usual way. The emergency definition is tightly structured: subjects must face a life-threatening situation, be unable to consent due to medical condition, and it must not be feasible to request consents from legal representatives within the relevant time window.
Beyond consent mechanics, the Regulations require that subjects receive a full explanation and information (reg. 19). There is also an explicit prohibition on coercion (reg. 20). These provisions are important for both ethics and enforceability: inadequate consent processes can become the basis for regulatory action and potential offences.
7. Safety measures, suspension, and termination (regs. 21–22)
When urgent safety issues arise, sponsors and investigators must implement urgent safety measures (reg. 21). The Regulations also provide for suspension or termination of a clinical trial (reg. 22). Practically, this links safety reporting and operational decision-making: once safety thresholds are met, the trial may need to pause or stop to protect subjects.
8. Records, traceability, and vigilance reporting (regs. 23–25)
The Regulations require a record of clinical trials (reg. 23). For CTGT products, there is an additional traceability obligation (reg. 23A) for “applicable CTGT products used in clinical trials.” Traceability is a compliance cornerstone for advanced therapies because it supports product accountability from manufacture through use.
Vigilance reporting is addressed through:
- Notifications of serious adverse events (reg. 24)
- Notifications of unexpected serious adverse drug reactions (reg. 25)
These duties ensure that HSA receives timely safety information so that regulatory action—such as protocol changes, risk communications, or trial suspension—can be considered.
9. Labelling requirements (reg. 26 and Second Schedule)
Labelling is regulated to prevent mix-ups and ensure that investigational and auxiliary products are appropriately identified. Regulation 26, together with the Second Schedule, sets out labelling requirements. For practitioners, labelling compliance is often a frequent audit focus because it intersects with manufacturing controls, storage, dispensing, and site-level accountability.
10. Confidentiality, publication, and offences (regs. 27–29)
The Regulations protect confidential information (reg. 27) and regulate publication of information on clinical trials (reg. 28). This balances transparency with protection of commercially sensitive and personal data. Finally, regulation 29 creates offences for contraventions of the Regulations. While the extract does not reproduce the offence wording, the existence of a dedicated offences provision signals that compliance is not optional and that breaches may carry legal consequences.
11. Application to pending trials (reg. 30)
The Regulations include transitional provisions for pending clinical trials. This matters for sponsors who started trials before later amendments or before the Regulations’ commencement, and for determining which procedural obligations apply at different times.
How Is This Legislation Structured?
The CT Regulations are organised into five parts:
- Part 1 (General): citation and commencement (reg. 1), definitions (reg. 2), and scope (reg. 3).
- Part 2 (Clinical trials): detailed operational and regulatory requirements, including sponsor/investigator roles (regs. 4–6), authorisation/notification (regs. 7–12), general duties (regs. 13–23A), vigilance (regs. 24–25), and labelling (reg. 26).
- Part 3 (Miscellaneous): confidentiality and publication (regs. 27–28).
- Part 4 (Offences): enforcement provisions (reg. 29).
- Part 5 (Application to pending clinical trials): transitional application (reg. 30).
Two schedules support the Regulations: the First Schedule sets out principles of good clinical practice, and the Second Schedule sets out labelling requirements.
Who Does This Legislation Apply To?
The Regulations apply primarily to sponsors and investigators conducting clinical trials in Singapore involving therapeutic products or applicable CTGT products (and excluding observational trials). They also affect healthcare institutions and trial sites, because the “place of clinical trial” and the conduct requirements impose operational constraints on where and how trial activities occur.
In practice, the compliance burden will be shared across the trial ecosystem: sponsor organisations, principal investigators, clinical research coordinators, pharmacy and labelling teams, and pharmacovigilance personnel. Where emergency consent is used, the Regulations also implicate legal representatives and consent decision-making processes.
Why Is This Legislation Important?
The CT Regulations provide the legal backbone for clinical trial governance in Singapore. For practitioners, their significance lies in the combination of (i) regulatory gatekeeping (authorisation/notification), (ii) binding operational duties (good clinical practice and adherence to submissions), and (iii) enforceable subject protection and safety reporting obligations.
From a risk management perspective, the Regulations create multiple compliance “pressure points”: consent documentation and information delivery, timely reporting of serious adverse events and unexpected serious adverse drug reactions, implementation of urgent safety measures, and correct labelling and traceability (especially for applicable CTGT products). These are the areas most likely to be scrutinised during audits, inspections, or incident investigations.
Finally, the existence of offences provisions means that non-compliance can escalate beyond administrative consequences. Sponsors and investigators should therefore treat the CT Regulations as a compliance framework that must be operationalised through trial protocols, standard operating procedures, training, and documented oversight.
Related Legislation
- Health Products Act (Cap. 122D)
- Health Products (Cell, Tissue and Gene Therapy Products) Regulations 2021
- Human Biomedical Research Act 2015
- Healthcare Services Act 2020
- Medical Registration Act 1997
- Dental Registration Act 1999
Source Documents
This article provides an overview of the Health Products (Clinical Trials) Regulations 2016 for legal research and educational purposes. It does not constitute legal advice. Readers should consult the official text for authoritative provisions.